141 related articles for article (PubMed ID: 26035984)
1. Worsening gradient of aortic stenosis with treatment of pulmonary arterial hypertension in scleroderma.
Pietras DA; Lopez FR; Peréz R; López-Candales A; Elwing J
Bol Asoc Med P R; 2015; 107(1):41-4. PubMed ID: 26035984
[TBL] [Abstract][Full Text] [Related]
2. Systemic hypertension in low-gradient severe aortic stenosis with preserved ejection fraction.
Eleid MF; Nishimura RA; Sorajja P; Borlaug BA
Circulation; 2013 Sep; 128(12):1349-53. PubMed ID: 23956211
[TBL] [Abstract][Full Text] [Related]
3. The acute effects of prostacyclin on pulmonary hemodynamics in patients with pulmonary hypertension secondary to systemic sclerosis.
Menon N; McAlpine L; Peacock AJ; Madhok R
Arthritis Rheum; 1998 Mar; 41(3):466-9. PubMed ID: 9506575
[TBL] [Abstract][Full Text] [Related]
4. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension.
Williams MH; Handler CE; Akram R; Smith CJ; Das C; Smee J; Nair D; Denton CP; Black CM; Coghlan JG
Eur Heart J; 2006 Jun; 27(12):1485-94. PubMed ID: 16682379
[TBL] [Abstract][Full Text] [Related]
5. New insights into the recognition, classification and management of systemic sclerosis-associated pulmonary hypertension.
Mullin CJ; Mathai SC
Curr Opin Rheumatol; 2017 Nov; 29(6):561-567. PubMed ID: 28817465
[TBL] [Abstract][Full Text] [Related]
6. [Systemic sclerosis associated pulmonary arterial hypertension: the pitfalls].
Hachulla E; Launay D; Le Pavec J; Mouthon L; Guillevin L; de Groote P
Presse Med; 2011 Apr; 40 Suppl 1():1S46-53. PubMed ID: 21536180
[TBL] [Abstract][Full Text] [Related]
7. [Vasodilator agents in pulmonary artery hypertension of systemic scleroderma].
Phlippoteau C; Brenot F; Blétry O; Simmonneau G; Duroux P
Rev Mal Respir; 1990; 7(3):249-54. PubMed ID: 2114030
[TBL] [Abstract][Full Text] [Related]
8. [Survival of patients with pulmonary arterial hypertension, associated with systemic sclerosis].
Ter Arkh; 2012; 84(5):24-8. PubMed ID: 22830207
[TBL] [Abstract][Full Text] [Related]
9. Screening for pulmonary arterial hypertension in patients with scleroderma--a New Zealand perspective.
Ghosh SK; Corkill MM; Hart HH; Ng KP
N Z Med J; 2014 Aug; 127(1400):30-8. PubMed ID: 25145365
[TBL] [Abstract][Full Text] [Related]
10. Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies.
Le Pavec J; Girgis RE; Lechtzin N; Mathai SC; Launay D; Hummers LK; Zaiman A; Sitbon O; Simonneau G; Humbert M; Hassoun PM
Arthritis Rheum; 2011 Aug; 63(8):2456-64. PubMed ID: 21538327
[TBL] [Abstract][Full Text] [Related]
11. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.
Mathai SC; Girgis RE; Fisher MR; Champion HC; Housten-Harris T; Zaiman A; Hassoun PM
Eur Respir J; 2007 Mar; 29(3):469-75. PubMed ID: 17079256
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary hypertension in isolated aortic stenosis. Hemodynamic correlations and follow-up.
Johnson LW; Hapanowicz MB; Buonanno C; Bowser MA; Marvasti MA; Parker FB
J Thorac Cardiovasc Surg; 1988 Apr; 95(4):603-7. PubMed ID: 3352293
[TBL] [Abstract][Full Text] [Related]
13. Does Sildenafil produce a sustained benefit in patients with pulmonary hypertension associated with parenchymal lung and cardiac disease?
Madden BP; Sheth A; Wilde M; Ong YE
Vascul Pharmacol; 2007; 47(2-3):184-8. PubMed ID: 17627899
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary arterial hypertension and systemic sclerosis relation: a single centre experience.
Demir N; Şahin A; Küçükşahin O; Kayacan O; Dinçer İ; Sayın T; Karnak D; Turgay M
Heart Lung Circ; 2014 Jul; 23(7):667-73. PubMed ID: 24613044
[TBL] [Abstract][Full Text] [Related]
15. Pulmonary arterial hypertension in the setting of scleroderma is different than in the setting of lupus: A review.
Bazan IS; Mensah KA; Rudkovskaia AA; Adonteng-Boateng PK; Herzog EL; Buckley L; Fares WH
Respir Med; 2018 Jan; 134():42-46. PubMed ID: 29413506
[TBL] [Abstract][Full Text] [Related]
16. Pulmonary arterial hypertension in systemic sclerosis: can we predict responders for successful therapy?
Sasahara AA
J Rheumatol; 2009 Apr; 36(4):665-6. PubMed ID: 19342719
[No Abstract] [Full Text] [Related]
17. Exercise during cardiac catheterization distinguishes between pulmonary and left ventricular causes of dyspnea in systemic sclerosis patients.
Hager WD; Collins I; Tate JP; Azrin M; Foley R; Lakshminarayanan S; Rothfield NF
Clin Respir J; 2013 Jul; 7(3):227-36. PubMed ID: 22789029
[TBL] [Abstract][Full Text] [Related]
18. [Management of borderline pulmonary arterial hypertension associated with connective tissue diseases].
Yoshifuji H; Kinoshita H
Nihon Rinsho Meneki Gakkai Kaishi; 2014; 37(6):454-61. PubMed ID: 25748129
[TBL] [Abstract][Full Text] [Related]
19. Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease.
Ahmadi-Simab K; Hellmich B; Gross WL
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():44-8. PubMed ID: 16919010
[TBL] [Abstract][Full Text] [Related]
20. Exercise echocardiography for the assessment of pulmonary hypertension in systemic sclerosis: a systematic review.
Baptista R; Serra S; Martins R; Teixeira R; Castro G; Salvador MJ; Pereira da Silva JA; Santos L; Monteiro P; Pêgo M
Arthritis Res Ther; 2016 Jul; 18(1):153. PubMed ID: 27368695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
